7Y6N

The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803

7Y6N の概要

• エントリーDOI: 10.2210/pdb7y6n/pdb
• EMDBエントリー: 33644
• 分子名称: Spike glycoprotein, Ab803 heavy chain, Ab803 light chain, ... (4 entities in total)
• 機能のキーワード: severe acute respiratory syndrome coronavirus-2 (sars-cov-2) spike trimer, covid-19, human neutralizing antibody, rbd, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 196440.09

構造登録者

Uchikubo, T.,Shirouzu, M. (登録日: 2022-06-21, 公開日: 2023-06-21, 最終更新日: 2024-11-13)

主引用文献

Takeshita, M.,Fukuyama, H.,Kamada, K.,Matsumoto, T.,Makino-Okamura, C.,Lin, Q.,Sakuma, M.,Kawahara, E.,Yamazaki, I.,Uchikubo-Kamo, T.,Tomabechi, Y.,Hanada, K.,Hisano, T.,Moriyama, S.,Takahashi, Y.,Ito, M.,Imai, M.,Maemura, T.,Furusawa, Y.,Yamayoshi, S.,Kawaoka, Y.,Shirouzu, M.,Ishii, M.,Saya, H.,Kondo, Y.,Kaneko, Y.,Suzuki, K.,Fukunaga, K.,Takeuchi, T.
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents.
Iscience, 26:106955-106955, 2023

PubMed Abstract: Several antibody therapeutics have been developed against SARS-CoV-2; however, they have attenuated neutralizing ability against variants. In this study, we generated multiple broadly neutralizing antibodies from B cells of convalescents, by using two types of receptor-binding domains, Wuhan strain and the Gamma variant as bait. From 172 antibodies generated, six antibodies neutralized all strains prior to the Omicron variant, and the five antibodies were able to neutralize some of the Omicron sub-strains. Structural analysis showed that these antibodies have a variety of characteristic binding modes, such as ACE2 mimicry. We subjected a representative antibody to the hamster infection model after introduction of the N297A modification, and observed a dose-dependent reduction of the lung viral titer, even at a dose of 2 mg/kg. These results demonstrated that our antibodies have certain antiviral activity as therapeutics, and highlighted the importance of initial cell-screening strategy for the efficient development of therapeutic antibodies.

PubMed: 37288342
DOI: 10.1016/j.isci.2023.106955

実験手法

ELECTRON MICROSCOPY (4.4 Å)